Loading...
Market
Which will be the first mRNA-based non-COVID vaccine to receive WHO prequalification by the end of 2025?
2
Resolution / Starting Odds
Influenza • 25%
Zika • 25%
HIV • 25%
Other • 25%
World Health Organization official announcements and prequalification lists
Story
Nobel Laureates' mRNA Technology Could Have Changed Pandemic Course If Available in May 2020
Nov 24, 2024, 02:50 PM
mRNA technology, developed by Nobel Prize laureates, has been pivotal in the rapid creation of COVID-19 vaccines. This technology, which has shown potential for developing vaccines against other diseases such as influenza, Zika, and HIV, could have significantly altered the course of the pandemic if available as early as May 2020 instead of February 2021. A new study also highlights the potential of mRNA in cancer immunotherapy, demonstrating its ability to speed up messenger RNA translation in cytoplasm and effectively inhibit tumor growth.
View original story
Similar markets
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%
Influenza • 25%
Zika Virus • 25%
HIV • 25%
Other • 25%
United States • 25%
European Union • 25%
Africa • 25%
Other • 25%
COVID-19 vaccine • 33%
Flu vaccine • 33%
Other mRNA vaccines • 33%
China • 25%
India • 25%
Brazil • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
AstraZeneca • 25%
Johnson & Johnson • 25%